Loading
JPXHealthcareBiotechnology
Latest quote
¥69.00
+¥1.00 · +1.47%
Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.
Latest quote
¥69.00
+¥1.00 · +1.47%
Regular session · JST · Market data may be delayed.
Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.
Day range
Current ¥69.00
52-week range
Current ¥69.00
Regular session · JST · Market data may be delayed.
Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.
Day range
Current ¥69.00
52-week range
Current ¥69.00
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 2.5B JPY | — | 800M JPY |
| Cost of goods sold | 1.43B JPY | 4.1M JPY | 6.04M JPY | 3.15M JPY | — |
| Gross profit | −1.43B JPY | −4.1M JPY | 2.49B JPY | −3.15M JPY | — |
| Research and development | 1.43B JPY | 1.5B JPY | 2B JPY | 1.66B JPY | 1.22B JPY |
| Selling, general, and administrative | 309.07M JPY | 297.51M JPY | 285.08M JPY | 184.85M JPY | 170.74M JPY |
| Operating expenses | 364.47M JPY | 1.8B JPY | 2.28B JPY | 1.84B JPY | 1.39B JPY |
| Depreciation and amortization | 2.7M JPY | 4.1M JPY | 6.04M JPY | 3.15M JPY | 700K JPY |
| Operating income | −1.79B JPY | −1.8B JPY | 212.06M JPY | −1.84B JPY | −587.67M JPY |
| Net income | −1.79B JPY | −1.83B JPY | 223.34M JPY | −1.78B JPY | −527.11M JPY |
Company facts updated Sep 17, 2026.
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
